Adocia SA ADR (ADOCY)
Adocia SA ADR (OTC: ADOCY) is a depositary receipt representing common stock of Adocia SA, a clinical-stage biotechnology company focused on therapeutic solutions for diabetes and obesity. The company’s BioChaperone platform is designed to help deliver therapeutic proteins and underpins a portfolio of insulin- and peptide-based programs. Reported products and candidates include BioChaperone Lispro U100 and U200, BioChaperone Combo, BioChaperone LisPram, and M1Pram, along with preclinical programs such as AdoShell Islets, AdOral Sema, and AdoGel Sema. Adocia also has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. covering development and commercialization of BioChaperone Lispro in China and selected Asian and Middle Eastern markets. The company was incorporated in 2005 and is headquartered in Lyon, France.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PINC-ADOCY
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
—
|
May 14, 2025
|
—
|
—
|
—
|
83.806 M
|
—
|
—
|
26.5%
|
—
|
—
|
—
|